Key Financial Results - Standalone (₹ in Lakhs)

Quarter Ended June 30, 2026 (Unaudited):

  • Total Income: ₹2,313.75
  • Total Expenses: ₹2,171.89
  • Profit Before Tax: ₹141.86
  • Net Profit After Tax: ₹141.86
  • Basic and Diluted EPS: ₹0.48

Comparative Standalone Performance:

  • Q1 FY26 (June 30, 2025): Net Profit of ₹61.43 lakh, EPS ₹0.21
  • Q4 FY26 (March 31, 2026): Net Profit of ₹265.06 lakh, EPS ₹0.90
  • Full Year FY26: Net Profit of ₹580.50 lakh, EPS ₹1.97

Key Financial Results - Consolidated (₹ in Lakhs)

Quarter Ended June 30, 2026 (Unaudited):

  • Profit Before Tax: ₹(178.69) (Loss)
  • Net Profit After Tax: ₹(178.69) (Loss)
  • Basic and Diluted EPS: ₹(0.61)

Comparative Consolidated Performance:

  • Q1 FY26 (June 30, 2025): Net Profit of ₹152.30 lakh, EPS ₹0.52
  • Q4 FY26 (March 31, 2026): Net Profit of ₹958.48 lakh, EPS ₹3.25

Joint Venture Performance

Brooks Steriscience Limited (Jointly Controlled Entity) recorded:

  • Revenue from operations: ₹1,751.30 lakh for Q1 FY27
  • Loss after tax: ₹654.18 lakh for Q1 FY27
  • Company's share of loss: ₹320.55 lakh recognized in consolidated results

The joint venture's financial results were reviewed by other auditors and incorporated into the consolidated results.

Segment-wise Performance (Standalone)

Quarter Ended June 30, 2026:

  • Trading Segment: Revenue ₹18.53 lakh, Segment Result ₹(13.79) lakh (Loss)
  • Manufacturing Segment: Revenue ₹2,277.55 lakh, Segment Result ₹185.10 lakh
  • Total Segment Revenue: ₹2,296.08 lakh
  • Total Segment Results: ₹171.31 lakh

Assets and Liabilities (Standalone as of June 30, 2026):

  • Total Segment Assets: ₹14,793.27 lakh
  • Total Segment Liabilities: ₹2,566.99 lakh
  • Paid-up Equity Share Capital: ₹2,945.72 lakh (Face Value ₹10 each)

Regulatory and Accounting Framework

The financial results were:

  • Prepared in accordance with Indian Accounting Standards (Ind AS)
  • Reviewed by the Audit Committee and approved by the Board of Directors
  • Subject to limited review by DMKH & Co, Chartered Accountants
  • The review report stated no material misstatements were found

Other Key Information

  • The company operates through two reportable business segments: Trading and Manufacturing
  • Manufacturing includes own manufacturing operations and loan-licensing business
  • No deferred tax asset recognized on business losses/depreciation due to absence of reasonable certainty of future taxable profit
  • Prior period figures have been regrouped and reclassified where necessary
  • Board meeting duration: 4:00 PM to 6:00 PM on August 13, 2026